Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial
European Stroke Journal · 01.03.2024 · 9 (1) · 265-273
DOI: 10.1177/23969873231200686 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, online erschienen am 01.03.2024. Verfasst von M P Cliteur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Brain Injuries. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Heart Foundation, Swedish Orphan Biovitrum AB.
Abstract (Originalsprache)
Background
Inflammation plays a vital role in the development of secondary brain injury after spontaneous intracerebral haemorrhage (ICH). Interleukin-1 beta is an early pro-inflammatory cytokine and a potential therapeutic target.
Aim
To determine the effect of treatment with recombinant human interleukin-1 receptor antagonist anakinra on perihematomal oedema (PHO) formation in patients with spontaneous ICH compared to standard medical management, and investigate whether this effect is dose-dependent.
Methods
ACTION is a phase-II, prospective, randomised, three-armed (1:1:1) trial with open-label treatment and blinded end-point assessment (PROBE) at three hospitals in The Netherlands. We will include 75 patients with a supratentorial spontaneous ICH admitted within 8 h after symptom onset. Participants will receive anakinra in a high dose (loading dose 500 mg intravenously, followed by infusion with 2 mg/kg/h over 72 h; n = 25) or in a low dose (loading dose 100 mg subcutaneously, followed by 100 mg subcutaneous twice daily for 72 h; n = 25), plus standard care. The control group (n = 25) will receive standard medical management. Outcomes: Primary outcome is PHO, measured as oedema extension distance on MRI at day 7 ± 1. Secondary outcomes include the safety profile of anakinra, the effect of anakinra on serum inflammation markers, MRI measures of blood brain barrier integrity, and functional outcome at 90 ± 7 days.
Discussion
The ACTION trial will provide insight into whether targeting interleukin-1 beta in the early time window after ICH onset could ameliorate secondary brain injury. This may contribute to the development of new treatment options to improve clinical outcome after ICH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.
- Department of Clinical Neurophysiology, University of Twente, Enschede, The Netherlands.
- Department of Neurology, Isala Hospital, Zwolle, The Netherlands.
ORCID-Profile: M P Cliteur, Fhbm Schreuder
Förderung
- Dutch Heart Foundation
- Swedish Orphan Biovitrum AB
Zitieren
APA
Cliteur, M. P., van der Kolk, A. G., Hannink, G., Hofmeijer, J., Jolink, W., Klijn, C., & Schreuder, F. (2024). Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial. European Stroke Journal, 9(1), 265-273. https://doi.org/10.1177/23969873231200686
Vancouver
Cliteur MP, van der Kolk AG, Hannink G, Hofmeijer J, Jolink W, Klijn C, et al. Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial. European Stroke Journal. 2024;9(1):265-273. doi:10.1177/23969873231200686
BibTeX
@article{Cliteur2024,
author = {Cliteur, M P and van der Kolk, A G and Hannink, G and Hofmeijer, J and Jolink, Wmt and Klijn, Cjm and Schreuder, Fhbm},
title = {Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial},
journal = {European Stroke Journal},
year = {2024},
volume = {9},
number = {1},
pages = {265--273},
doi = {10.1177/23969873231200686}
}
EUVIMED